A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Veliparib (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 15 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 15 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.